Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov;99(21):1597-602.
doi: 10.1136/heartjnl-2013-303698. Epub 2013 Jun 4.

The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?

Tjeerd-Pieter van Staa  1 , Liam Smeeth, Edmond S-W Ng, Ben Goldacre, Martin Gulliford
Affiliations
Free PMC article

The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?

Tjeerd-Pieter van Staa et al. Heart. 2013 Nov.
Free PMC article

Abstract

Objective: To evaluate targeting of statin prescribing for primary prevention to those with high cardiovascular disease (CVD) risk.

Design: Two cohort studies including the general population and initiators of statins aged 35-74 years.

Setting: UK primary care records in the Clinical Practice Research Datalink.

Patients: 3.8 million general population patients and 300 914 statin users.

Intervention: Statin prescribing.

Main outcome measures: Statin prescribing by CVD risk; observed 5-year CVD risks; variability between practices.

Results: Statin prescribing increased substantially over time to patients with high 10-year CVD risk (≥ 20%): 7.0% of these received a statin prior to 2007, and 30.4% in 2007 onwards. Prescribing to patients with low risk (<15%) also increased (from 1.9% to 5.0%). Only about half the patients initiating statin treatment were high risk according to CVD risk score. The 5-year CVD risks, as observed during statin treatment, reduced over calendar time (from 17.0% to 7.1%). There was a large variation between general practices in the percentage of high-risk patients prescribed a statin in 2007 onwards, ranging from 8.2% to 61.5%. For low-risk patients, these varied from 2.1% to 29.1%.

Conclusions: There appeared to be substantive overuse in low CVD risk and underuse in high CVD risk (600 000 and 850 000 patients, respectively, in the UK since 2007). There is wide variation between practices in statin prescribing to patients at high CVD risk. There is a clear need for randomised trials for the best strategy to target statin treatment and manage CVD risk for primary prevention.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Percentage of patients with low risk (<15%) or high risk (≥20%) prescribed a statin in 2007 onwards, stratified by practice. X-axis: percentage of statin prescribing in a practice to low-risk patients. Y-axis: percentage of statin prescribing in a practice to high-risk patients. Each X corresponds to one practice.
See this image and copyright information in PMC

Comment in

References

    1. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011;(1):CD004816. - PMC - PubMed
    1. Cooper A, Nherera L, Calvert N, et al. Clinical Guidelines and Evidence Review for Lipid Modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2007
    1. British Cardiac Society, British Hypertension Society, Diabetes UK JBS guidelines on prevention of CVD in clinical practice. Heart 2005;91:1–52 - PMC - PubMed
    1. Putting prevention first—vascular checks: risk assessment and management (April 2008) NHS Health Check Programme. ww.healthcheck.nhs.uk/document.php?o=224
    1. Anderson KM, Odell PM, Wilson PWF, et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293–8 - PubMed

Publication types

MeSH terms

Substances